Brainvivo is the next generation of brain imaging technologies, which converts clinical MRI scanners into virtual microscopes.
Brainvivo uses its novel HD-MRI based, non-invasive neuromarkers, to reveal new medical information based on brain micro-structure. We equipped physicians with innovative information for early diagnosis, monitoring and personalized treatment of neurodegenerative diseases and brain disorders
Early characterization and monitoring, as well as personalized therapy, are currently the leading challenges in the field of brain health. In neurodegenerative diseases and brain disorders, interventions have usually been made following the occurrence of severe symptoms, where probability of recovery is extremely limited.
To date, the most widely used radiologic assessment of most brain diseases are made by conventional MRI techniques that date back decades. These techniques are also in use in the diagnostic process of Multiple Sclerosis (MS), an illness of young to middle-aged adults which characterized by massive axonal damage (Brain wiring deformation). Despite their widespread use, conventional MRI techniques are only poorly correlate with MS disease and its progression, severely hampering the practitioners’ capacity to successfully diagnosis and treat MS disease. As such, the development and application of sensitive and specific diagnostic tools capable of resolving MS in its early stages remains absolutely imperative.
Our novel technology can overcome the conventional MRI resolution limitation by tracking water molecules’ movement within brain tissues. The latter allows the measurements of the micro-elements of brain wiring on a microscopic level, which up to now were possible only in post mortem tissues. Our technology has recently succeeded to extract novel medical information on the cellular level by allowing the measurement of brain wiring diameter sizes (axon diameter) for the first time.
We succeeded to demonstrated that axon diameter is significantly lower (20% smaller) in patients with MS than the healthy population using a short HD-MRI scan (~10 min). Moreover, we succeeded to early detect MS patients in their pre-clinical stage with 92% success rate. This novel neuromarker enables the detection of abnormalities in early stages of MS, improves MS monitoring and management, and supports personalized treatment
Assi (Assaf) Horowitz
Assi (Assaf) Horowitz is a highly motivated entrepreNeuro-Scientist, dedicated to developing life-changing innovations in medicine, which has been working in both academia and the life-science industry in the past 9 years. Assi graduated the Israeli Naval Academy and serves as a captain of a battleship in the Israeli navy (2001-2007) and released from service holding the rank of major. Mr. Horowitz was the Senior Project Manager of Strauss Center, managing the establishment of an advance MRI center in Tel Aviv University along with the global Siemens corporation and Siemens Israel. Assi was also the VP of Sales and Marketing at Inovytec Medical Solutions Ltd, and in that role he established the company’s distribution network worldwide, designed, developed and executed the company’s sales and marketing strategies as well as conducted business development. In 2010, he initiated the implementation of AxCaliber framework for clinical MRI scanner and in 2013 made the technology clinically feasible for human subjects. Assi holds a BSc in biotechnology and an MSc in Neurobiology and completing his PhD in Sagol School of Neuroscience in the upcoming year.
Mr. Horowitz published his work ‘In vivo correlation between axon diameter and conduction velocity in the human brain’ in 2014 and recently submitted his work ‘A Novel biomarker for diagnosis of Multiple Sclerosis by measuring in-vivo axon diameter changes’. His work has been selected for an oral presentation in the ISMRM 2013, OHBM 2014 conferences and was awarded as one of the best research in multiple sclerosis field in 2016 (ECTRIMS 2016).